Fresh2 Group Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Fresh2 Group şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-528.8%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-528.8%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

AnPac Bio announces plan to implement ADS ratio change

Oct 18

AnPac Bio-Medical Science announces management changes

Oct 03

AnPac Bio-Medical Science signed equity investment totaling $3.67M with new investor Group

Sep 27

AnPac Bio (ANPC) skyrockets 136% on advancement in detecting pre-cancer diseases

Dec 14

Industry Analysts Just Upgraded Their AnPac Bio-Medical Science Co., Ltd. (NASDAQ:ANPC) Revenue Forecasts By 55%

Dec 11

AnPac Bio-Medical rallies on Q3 record test volume; FY20 revenue estimated at +100%

Nov 25

AnPac Bio's Chinese company secures COVID-19 nucleic acid test certification; shares +33%

Nov 02

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: FRES şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: FRES şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Fresh2 Group Piyasaya Karşı Temettü Getirisi

FRES temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (FRES)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.2%
Sektör Ortalaması (Biotechs)	2.3%
Analist tahmini (FRES) (3 yıla kadar)	n/a

Önemli Temettü: FRES şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, FRES şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: FRES şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: FRES herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Fresh2 Group Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

New major risk - Financial data availability

High number of new and inexperienced directors

Fresh2 Group Limited Announces Receipt of A Delinquency Compliance Alert Notice from Nasdaq

Fresh2 Group Limited announced delayed annual 10-K filing

Fresh2 Group Ltd Launches TikTok Video E-commerce Venture, Bridging the Gap Between Food Sources and Consumers

Fresh2 Group Receives Deficiency Notice from the Nasdaq Regarding Fails to Comply with the $1 Minimum Bid Price Required for Continued Listing on the Nasdaq Capital Market Under Nasdaq Listing Rule 5550(a)(2)

Fresh2 Group Limited Appoints Zhijun (Michael) Liang as Independent Director, Effective January 1, 2024

Ningkasai Technology (Shanghai) Co., Ltd. entered into a share purchase agreement to acquire Changhe Bio-Medical Technology (Yangzhou) Co., Ltd. from Fresh2 Group Limited (NasdaqCM:FRES) for CNY 1.

Fresh2 Group Limited (NasdaqCM:FRES) acquired Roxe Holding Inc.

Fresh2 Group Limited Appoints Yidong Hu as Chief Strategy Officer

Fresh2 Group Ltd. Regains Compliance with Nasdaq Listing Requirements

Fresh2 Group Limited Announces the Resignation of Chris Chang Yu as Co-Chief Executive Officer

AnPac Bio-Medical Science Co., Ltd. (NasdaqCM:ANPC) entered into an agreement to acquire Fresh2 Ecommerce Inc for $2.1 million.

AnPac Bio-Medical Science Co., Ltd. announced that it expects to receive $5 million in funding

AnPac Bio-Medical Science Announces Regaining Compliance with Nasdaq Listing Requirement

AnPac Bio-Medical Science Co., Ltd. Announces Board Resignations

AnPac Bio Granted Continued Listing by Nasdaq Hearing Panel

AnPac Bio announces plan to implement ADS ratio change

Anpac Bio-Medical Science Co., Ltd. Appoints Xiaoyu Li as Chief Financial Officer

AnPac Bio-Medical Science announces management changes

AnPac Bio-Medical Science Co., Ltd. announced that it expects to receive $3.67 million in funding

AnPac Bio-Medical Science signed equity investment totaling $3.67M with new investor Group

AnPac Bio-Medical Science Appeals Nasdaq Delisting Notice; Hearing Granted and Scheduled for October 20, 2022

AnPac Bio-Medical Science Co., Ltd. Appeals Nasdaq Delisting Notice

Less than half of directors are independent

AnPac Bio-Medical Science Co., Ltd. Announces Executive Appointments

AnPac Bio appoints Yuyang Cui as co-chief executive officer

AnPac Bio-Medical Science Co., Ltd. Approves CEO Changes

AnPac Bio-Medical Science Co., Ltd. announced that it expects to receive $1.5 million in funding

Anpac Bio-Medical Science Co., Ltd. Appoints Chris Chang Yu as Co-CEO of the Company

AnPac Bio-Medical Science Co., Ltd. announced delayed 20-F filing

High number of new directors

AnPac Bio-Medical Science Co., Ltd. Announces Executive Changes

AnPac Bio-Medical Science Announces Receipt of Staff Delisting Determination from Nasdaq

AnPac Bio-Medical Science Co., Ltd. Files CDA Device for Breakthrough Medical Device Designation Request with the FDA

AnPac Bio Class III Medical Device Passes Extensive NMPA Registration Tests and Will Start Clinical Trial in first quarter of 2022

Third quarter 2021 earnings: Revenues miss analyst expectations

Second quarter 2021 earnings released: CN¥2.16 loss per share (vs CN¥3.15 loss in 2Q 2020)

AnPac Bio-Medical Science Co., Ltd. Completes Major Preclinical Study, Files with National Medical Products Administration for Registration Testing of Its Multi-Cancer CDA Device

AnPac Bio’s First Disease Treatment Patent Granted, and Its Cancer Treatment Project Secured Multi-Million Dollar Funds

AnPac Bio stock soars 15% after securing first disease treatment patent in U.S.

Consensus revenue estimates fall to CN¥34.5m

First quarter 2021 earnings released: CN¥1.93 loss per share (vs CN¥2.56 loss in 1Q 2020)

AnPac Bio Launches Novel Cancer Treatment Technology and Product Joint Venture - Utilizing Findings from 10 Years of Early-Stage Cancer Detection Work Involving over 222,200 Sample Database

Full year 2020 earnings released

New 90-day high: US$7.70

NMPA Approves Starting of Registration Testing of AnPac Bio Class III Medical Device (For Lung Cancer Auxiliary Diagnosis Utility)

AnPac Bio wins new US patent for multi-cancer detection

AnPac Bio-Medical Science Co., Ltd. Makes Significant Progress in Detecting Pre-Cancer Diseases and Recorded over 20 Types of Pre-Cancer Diseases

AnPac Bio (ANPC) skyrockets 136% on advancement in detecting pre-cancer diseases

Industry Analysts Just Upgraded Their AnPac Bio-Medical Science Co., Ltd. (NASDAQ:ANPC) Revenue Forecasts By 55%

New 90-day high: US$7.14

AnPac Bio-Medical rallies on Q3 record test volume; FY20 revenue estimated at +100%

Anpac Bio-Medical Science Co., Ltd. Appoints Jianhua Shao as Independent Director and Member of Compensation Committee

AnPac Bio-Medical Science Co., Ltd. Completes COVID-19 Antibody Test Verification

AnPac Bio's Chinese company secures COVID-19 nucleic acid test certification; shares +33%

New 90-day low: US$3.38

New 90-day low: US$4.20

First half earnings released

New 90-day low - US$4.80

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin